AC Immune (ACIU) Cash & Equivalents (2014 - 2026)

AC Immune (ACIU) has reported Cash & Equivalents for 13 consecutive years, with $24.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 110162.74% year-over-year to $24.5 billion; the TTM figure through Mar 2026 stood at $24.5 billion (up 110162.74% YoY), while the FY2025 annual figure was $32.3 million, down 21.95% from the prior year.
• Cash & Equivalents advanced to $24.5 billion in Q1 2026 per ACIU's latest filing, from $33.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $24.5 billion in Q1 2026 and bottomed at $62624.2 in Q1 2022.
• Historically, Cash & Equivalents has averaged $1.5 billion across 5 years, with a median of $41.4 million in 2024.
• Annual changes were most pronounced in 2025 — Cash & Equivalents sank 66.01% — and 2026, when it soared 110162.74%.
• AC Immune's Cash & Equivalents stood at $32.8 million in 2022, then jumped by 169.9% to $88.5 million in 2023, then tumbled by 53.21% to $41.4 million in 2024, then declined by 19.04% to $33.5 million in 2025, then jumped by 72916.66% to $24.5 billion in 2026.
• Business Quant data shows ACIU's Cash & Equivalents at $24.5 billion in Q1 2026, $33.5 million in Q4 2025, and $34.7 million in Q3 2025.